New York, May 27, 2022 (GLOBE NEWSWIRE) — The Insight Partners published latest research study on “Chemotherapy-Induced Peripheral Neuropathy Market Forecast to 2028 – COVID-19 Impact and Global Analysis By Drug Class (Steroids, Antidepressants, Anti-Seizure, and Narcotics) and Distribution Channel (Retail Pharmacy, Hospital Pharmacy, and Online Pharmacy)”, the global chemotherapy-induced peripheral neuropathy market growth is driven by the technological advancements in treatment and diagnosis, and increasing demand for cost-efficient therapeutics, the increasing prevalence of cancer and increasing preference for chemotherapy, the growing clinical trials for chemotherapeutic drugs. However, adverse effects related to the treatment may hinder the market growth.
The Sample Pages Showcases Content Structure and Nature of Information Included in This Research Study Which Presents A Qualitative and Quantitative Analysis: https://www.theinsightpartners.com/sample/TIPRE00028941/
| Report Coverage | Details |
| Market Size Value in | US$ 813.48 Million in 2021 |
| Market Size Value by | US$ 1,174.26 Million by 2028 |
| Growth rate | CAGR of 5.4% from 2021 to 2028 |
| Forecast Period | 2021-2028 |
| Base Year | 2021 |
| No. of Pages | 151 |
| No. Tables | 57 |
| No. of Charts & Figures | 74 |
| Historical data available | Yes |
| Segments covered | Drug Class, and Distribution Channel |
| Regional scope | North America; Europe; Asia Pacific; Latin America; MEA |
| Country scope | US, UK, Canada, Germany, France, Italy,… |
